OBJECTIVES: We evaluated and compared tumor antigen precursor protein (TAPP) profiles in adult and pediatric brain tumors of 31 genes related to tumor associated antigens (TAA) for possible use in immunotherapy. Antigens were selected based on their potential to stimulate T cell responses against tumors of neuroectodermal origin. METHODS: Thirty-seven brain tumor specimens from 11 adult and 26 pediatric patients were analyzed by quantitative real-time PCR for the relative expression of 31 TAPP mRNAs. The age range of adults (4F:7M) was 27-77 years (median 51.5 +/- 14.5 years) and for pediatrics (12F:14M) was 0.9-19 years (median 8.3 +/- 5.5 years). Histological diagnoses consisted of 16 glioblastomas, 4 low grade astrocytomas, 10 juvenile pilocytic astrocytomas, and 7 ependymomas. RESULTS: The adult gliomas expressed 94% (29 of 31) of the TAPP mRNAs evaluated compared with pediatric brain tumors that expressed 55-74% of the TAPP mRNAs, dependent on tumor histological subtype. Four types of TAPP expression patterns were observed: (1) equal expression among adult and pediatric cases, (2) greater expression in adult than pediatric cases, (3) expression restricted to adult GBM and (4) a random distribution. The pediatric brain tumors lacked expression of some genes associated with engendering tumor survival, such as hTert and Survivin. CONCLUSIONS: The potential TAA targets identified from the TAPP profiles of 31 genes associated with adult and pediatric brain tumors may help investigators select specific target antigens for developing dendritic cell- or peptide-based vaccines or T cell-based immunotherapeutic approaches against brain tumors.
OBJECTIVES: We evaluated and compared tumor antigen precursor protein (TAPP) profiles in adult and pediatric brain tumors of 31 genes related to tumor associated antigens (TAA) for possible use in immunotherapy. Antigens were selected based on their potential to stimulate T cell responses against tumors of neuroectodermal origin. METHODS: Thirty-seven brain tumor specimens from 11 adult and 26 pediatric patients were analyzed by quantitative real-time PCR for the relative expression of 31 TAPP mRNAs. The age range of adults (4F:7M) was 27-77 years (median 51.5 +/- 14.5 years) and for pediatrics (12F:14M) was 0.9-19 years (median 8.3 +/- 5.5 years). Histological diagnoses consisted of 16 glioblastomas, 4 low grade astrocytomas, 10 juvenile pilocytic astrocytomas, and 7 ependymomas. RESULTS: The adult gliomas expressed 94% (29 of 31) of the TAPP mRNAs evaluated compared with pediatric brain tumors that expressed 55-74% of the TAPP mRNAs, dependent on tumor histological subtype. Four types of TAPP expression patterns were observed: (1) equal expression among adult and pediatric cases, (2) greater expression in adult than pediatric cases, (3) expression restricted to adult GBM and (4) a random distribution. The pediatric brain tumors lacked expression of some genes associated with engendering tumor survival, such as hTert and Survivin. CONCLUSIONS: The potential TAA targets identified from the TAPP profiles of 31 genes associated with adult and pediatric brain tumors may help investigators select specific target antigens for developing dendritic cell- or peptide-based vaccines or T cell-based immunotherapeutic approaches against brain tumors.
Authors: John S Yu; Gentao Liu; Han Ying; William H Yong; Keith L Black; Christopher J Wheeler Journal: Cancer Res Date: 2004-07-15 Impact factor: 12.701
Authors: Hideho Okada; Frank S Lieberman; Howard D Edington; Timothy F Witham; Mark J Wargo; Quan Cai; Elaine H Elder; Theresa L Whiteside; S Clifford Schold; Ian F Pollack Journal: J Neurooncol Date: 2003 Aug-Sep Impact factor: 4.130
Authors: S Rutkowski; S De Vleeschouwer; E Kaempgen; J E A Wolff; J Kühl; P Demaerel; M Warmuth-Metz; P Flamen; F Van Calenbergh; C Plets; N Sörensen; A Opitz; S W Van Gool Journal: Br J Cancer Date: 2004-11-01 Impact factor: 7.640
Authors: Lisheng Ge; Neil T Hoa; Zechariah Wilson; Gabriel Arismendi-Morillo; Xiao-Tang Kong; Rajeev B Tajhya; Christine Beeton; Martin R Jadus Journal: Int Immunopharmacol Date: 2014-07-12 Impact factor: 4.932
Authors: Neha Kamran; Alexandra Calinescu; Marianela Candolfi; Mayuri Chandran; Yohei Mineharu; Antonela S Asad; Carl Koschmann; Felipe J Nunez; Pedro R Lowenstein; Maria G Castro Journal: Expert Opin Biol Ther Date: 2016-07-27 Impact factor: 4.388
Authors: Kate L Erickson; Michelle J Hickey; Yuki Kato; Colin C Malone; Geoffrey C Owens; Robert M Prins; Linda M Liau; Noriyuki Kasahara; Carol A Kruse Journal: J Vis Exp Date: 2015-02-11 Impact factor: 1.355
Authors: Michelle J Hickey; Colin C Malone; Kate L Erickson; Martin R Jadus; Robert M Prins; Linda M Liau; Carol A Kruse Journal: J Transl Med Date: 2010-10-14 Impact factor: 5.531
Authors: Robert M Prins; Xiaoyan Wang; Horacio Soto; Emma Young; Dominique N Lisiero; Brendan Fong; Richard Everson; William H Yong; Albert Lai; Gang Li; Timothy F Cloughesy; Linda M Liau Journal: J Immunother Date: 2013-02 Impact factor: 4.456